What Is It?
A small-molecule enzyme inhibitor that blocks NNMT — not a peptide. First characterized in 2017. While most NAD+ strategies supply more precursors, this one takes a fundamentally different approach.
How Does It Work?
NMN and NR supply more NAD+ precursors. They fill the bucket. 5-Amino-1MQ does the opposite. It plugs the drain. Blocks NNMT enzyme activity to stop nicotinamide methylation in fat cells. Intracellular NAD+ rises 1.2-1.6 fold. Suppresses lipogenesis and upregulates GLUT4 glucose transport. Three problems — fat storage, NAD+ availability, glucose uptake — solved with one enzyme target.
Primary Benefits (research suggests)
- 30-40% reduction in fat cell size in studies
- Improved glucose uptake
- Grip strength improvements in aged mice
Run the Numbers
Calculate your 5-Amino-1MQ dosing — capsule strength, daily totals, and protocol planning. Free, no login required.
Open the Calculator →The Honest Part
- Zero human clinical trials.
- Every benefit claim is from rodents and cell cultures.
- Not FDA-approved.
- Some clinics are administering it ahead of safety data.
- Long-term safety unknown — most studies under 3 months.
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track 5-Amino-1MQ in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →